학술논문
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, November 2023, 24(11):1219-1228)
Subject
Language
English
ISSN
14745488
14702045
14702045